Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-11-15
2005-11-15
McKenzie, Thomas C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S217070, C514S252160, C514S253040, C514S262100, C514S303000, C540S599000, C540S600000, C544S262000, C544S362000, C546S119000
Reexamination Certificate
active
06964957
ABSTRACT:
Pyrazole compounds represented by the formula:are described. The pyrazole compounds and pharmaceutical compositions containing them may be used in inhibiting ERAB or HADH2 activity and in treating ERAB, HADH2 or amyloid-β mediated diseases and conditions.
REFERENCES:
patent: 3165520 (1965-01-01), Schmidt et al.
patent: 4666908 (1987-05-01), Hamilton
patent: 5047404 (1991-09-01), Coates et al.
patent: 5272147 (1993-12-01), Bell et al.
patent: 5294611 (1994-03-01), Venkatesan et al.
patent: 5294612 (1994-03-01), Bacon et al.
patent: 5426107 (1995-06-01), Bell et al.
patent: 5541187 (1996-07-01), Bacon et al.
patent: 5656627 (1997-08-01), Bemis et al.
patent: 5656629 (1997-08-01), Bacon et al.
patent: 5707998 (1998-01-01), Takase et al.
patent: 6194410 (2001-02-01), Bos et al.
patent: 6197774 (2001-03-01), Yamada et al.
patent: 6207829 (2001-03-01), Dunn et al.
patent: 6262302 (2001-07-01), Wu et al.
patent: 0 463 756 (1992-02-01), None
patent: 0 526 004 (1993-03-01), None
patent: WO 94/28902 (1994-12-01), None
patent: WO 95/34563 (1995-12-01), None
patent: WO 96/16644 (1996-06-01), None
patent: WO 98/40484 (1998-09-01), None
patent: WO 98/49166 (1998-11-01), None
patent: WO 99/18987 (1999-04-01), None
patent: WO 99/30710 (1999-06-01), None
patent: WO 00/24742 (2000-05-01), None
patent: WO 00/76969 (2000-12-01), None
patent: WO 00/76987 (2000-12-01), None
patent: WO 00/76988 (2000-12-01), None
patent: WO 01/12598 (2001-02-01), None
G. Y. Wen, S. Y. Yang, W. Kaczmarski, X. Y. He and K. S. pappas, Brain Research, vol. 954, Issue 1, Nov. 1, 2002, pp. 115-122.
Rob Ofman, Jos P. N. Ruiter, Marike Feenstra, Marinus Duran,1Bwee Tien Poll-The, Johannes Zschocke, Regina Ensenauer, Willy Lehnert, Jörn Oliver Sass, Wolfgang Sperl, and Ronald J. A. Wanders, Am. J. Hum. Genet., 72:1300-1307, 2003.
Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977
Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
International Search Report, PCT/US 01/41795, filed Aug. 17, 2001 (mailed Jan. 11, 2002).
Auzzi et al.,Boll. Chim. Farm., 112, 521-8 (1973).
Bagshawe,Drug Dev. Res., 34, 220-230 (1995).
Bergmann, R. et al.,J. Med. Chem., 33, 492-504 (1990).
Bergmann et al.,J. Chem. Soc., 1 (11), 2795-802 (1979).
Bertolini et al.,J. Med. Chem., 40, 2011-2016 (1997).
Binstock et al.,Methods Enzymol.71, 403-411 (1981).
Bodor,Advances in Drug Res., 13, 255-331 (1984.
Buck, J. et al,J. Chem. Soc., Perkin Trans. 1(1), 67-73 (1992).
Bundgaard,Design of Prodrugs(Elsevier Press 1985).
Dear et al.,J. Chromatogr. B, 748, 281-293 (2000).
Fukuyama et al.,Tetrahedron Letters, 26, No. 51, 6292 (1985).
Ganem et al,Chemtracts: Org. Chem., 1(5), 413-14 (1988).
Glenner, et al.,Biochem. Biophys. Res. Commun., 120:885-890 (1984).
Hagiwara et al.,J. Chem. Soc., Chem. Commun., 1351-1353 (1987).
He et al.,J. Bio. Chem.vol. 273. No. 17, pp. 10741-10746 (1998).
He et al.,J. Biol. Chem., 274(21), pp. 15014-15019(1999).
Hwu et al.,J. Org. Chem., 52, 188-191 (1987).
Kang et al.,Nature, vol. 325, pp. 733-736 (1987).
Koziara, A. et al.,Synthesis, 527-529 (1979).
Kuzuya et al.,Nippon Kagaku Kaishi, 12, 1746-53 (1986).
Ladduwahetty,Contemp. Org. Synth., 4(4), 309-325 (1997).
Larsen,Design and Application of Prodrugs, Drug Design and Development(Krogsgaard-Larsen et al., eds., Harwood Academic Publishers, (1991).
Masui et al, M., Chemtracts:Org. Chem., I(5), 385-7 (1988).
Petitou et al.,Tetrahedron Letters, 29, No. 12, 1389-1390 (1988).
Prox et al.,Xenobiol, vol. 3, No. 2, 103-112 (1973).
Oppermann et al.,FEBS Lett, 451(3), pp. 238-242 (1999).
Schultz et al.,Stereosel. React. Met.-Act. Mol., Proc. Symp., 2nd(1995), Meeting Date 1994, 45-48. Publisher: Vieweg, Wiesbaden, Germany: Roush,Chemstracts.
Secrist et al.,J. Med. Chem.,(1993)36(13), 1847-1854.
Selkoe,Annual Review of Neuroscience, vol. 17, pp. 489-517 (1994).
Shan et al.,J. Pharm. Sci., 86 (7), 765-767 (1997).
Sieburth et al,J. Org. Chem., 64(3), 950-953 (1999).
Small et al.,Journal of Neurochemistry, vol. 73, No. 2, pp. 443-449 (1999).
Sorato, C.,Chemtracts: Org. Chem., 2(4), 255-7 (1989).
Spraul et al.,J. Pharmaceutical&Biomedical Analysis, vol. 10, No. 8, 601-605 (1992).
Still et al.,J. Org. Chem., 43, No. 14, 2923-2925 (1978).
Storey et al.,Neuropathology And Applied Neurobiology, vol. 25, pp. 81-97 (1999).
T. Greene and P. Wuts, Protecting Groups in Chemical Synthesis, Index (3rd ed.), John Wiley & Sons, NY (1999).
Walters et al.,Tetrahedron Lett., 36(42), 7575-8 (1995).
Wilson et al.,Journal of Neuropathology And Experimental Neurology, vol. 58, No. 8,pp. 787-794 (1999).
Yamawaki,Chem. Lett., 1143-1146 (1981).
Yan et al.,J. Biol. Chem., vol. 274, No. 4, pp. 2145-2156 (1999).
Yan et al.,Nature, vol. 389, pp. 689-695 (1997).
Yao e tal.,Bioorg. Med. Chem. Lett., 8(6), 699-704(1988).
Abreo Melwyn A.
Agree Charles S.
Meng Jerry J.
Agouron Pharmaceuticals , Inc.
McKenzie Thomas C.
Richardson Peter C.
Yakovleva Galina M.
Zielinski Bryan C.
LandOfFree
Fused pyrazole compounds, pharmaceutical compositions, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused pyrazole compounds, pharmaceutical compositions, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused pyrazole compounds, pharmaceutical compositions, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3476880